Table 5 Previous literature on salvage surgery after systemic drug therapy in non-small cell lung cancer
No. | Author (year) | N | Prior drug therapy | Operative mode | *1Blood loss volume (ml) | *1Operation time (min) | Morbidity (%) | Mortality (%) | OS | PFS |
|---|---|---|---|---|---|---|---|---|---|---|
1 | Hishida (2010) | 9 | TKI | L 6, BL 1, P 2 | NA | NA | 11 | 90 days 0 | 3-year OS 50% Median OS 32 m | 3-year PFS 25 Median PFS 6 m |
2 | Song (2020) | 9 | TKI | L 9 | 120 (100–840) | 110 (80–170) | 11 | 90 days 0 | Median OS 17 m | NA |
3 | Li (2021) | 18 | TKI | L 18 | NA | NA | ≧ G4 0 | 90 days 0 | Median OS not reached | Median PFS after initial TKI 23 m |
4 | Ohtaki (2021) | 36 | TKI | W 2, S 3, L 28, BL 1, P 2 | 90 (16–340) | 225 (153–267) | 25 (≧ G3 6) | 90 days 0 | 3-year OS 75% | 3-year PFS 22% |
5 | Bott (2018) | 9 | ICI | W 3, L 4, BL 2 | 98 (3–500) | 168 (45–394) | 42 (≧ G3 12) | 90 days 0 | NA | |
6 | Bertolaccini (2021) | 8 | Cytotoxic agent plus ICI | L 7, P 1 | NA | 179 (122–246) | 22 (≧ G3 12) | 90 days 0 | *2NA | |
7 | Smith (2021) | 6 | ICI (17%), cytotoxic agent plus ICI (83%) | W 1, S 1, L 4 | 125 (65–300) | 125 (10–400) | 17 (≧ G3 0) | 90 days 0 | *3NA | |
8 | Present study (2022) | 32 | Cytotoxic agent (38%), TKI (50%), ICI (3%), cytotoxic agent plus ICI (9%) | W 5, S 2, L 37, P 2 | 100 (0–1006) | 218 (47–444) | 19 (≧ G3 11) | 30 days 0 90 days 3 | 5-year OS 66% | 5-year PFS 21% |